ADC Therapeutics to report third quarter 2026 financial results on November 9

ADC Therapeutics, the Lausanne-based biopharmaceutical company, has scheduled the release of its third-quarter 2026 financial results for November 9, 2026. The report will be published on the company’s investor relations portal.

The firm specializes in the development of antibody-drug conjugates, specifically its lead product ZYNLONTA. The treatment is currently utilized for relapsed or refractory diffuse large B-cell lymphoma, having secured regulatory approvals in both the U.S. and European markets.

The upcoming financial disclosure follows a period of rigorous testing and regulatory navigation, particularly regarding the LOTIS clinical trial series. Stakeholders are monitoring the company’s revenue growth trajectory and the ongoing efforts to expand the clinical indications for its primary therapeutic assets.